Table 2.

Details of contemporary HCC risk scores

Risk score	Components	Original cohort	Validation (V)/performance (P)
LSM-Based Model (2013)56	Age Gender HBV DNA LSM	Asian cohort (mixed treatment status)	V; none in other cohorts
LSM-HCC (2014)57	Age Albumin HBV DNA LSM	Asian cohort (mixed treatment status)	Modification of CU-HCC: V: Asian cohorts (mixed treatment status)59 60 P: superior to conventional risk scores and PAGE B,60 similar to mREACH-B59 60
mREACH-B (2014)58	Age Gender ALT HBeAg status LSM	Treated Asian cohort	Modification of REACH-B: V: Asian cohorts (mixed treatment status)48 59 60 P: superior to conventional risk scores48 59and contemporary risk scores59 60
PAGE-B (2016)51	Age Gender Platelets	Treated Caucasian cohort	V: treated Asian cohorts52 54 60 P: similar or superior to conventional risk scores,52 similar to mPAGE-B54 60 but inferior to LSM-HCC and mREACH-B60
mPAGE-B (2018)53	Age Gender Platelets Albumin	Treated Asian cohort	Modification of PAGE-B: V: treated Asian cohort54 P: similar or superior to conventional risk scores54

ALT, alanine aminotransferase; CU-HCC, cumulative HCC; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LSM, liver stiffness measurement; mPAGE-B, modified PAGE-B.